Merck has also been focusing on vaccines as well as drugs to combat cancer and diabetes. (AP Photo/Matt Rourke, File)
Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
Merck & Co. agreed to purchase Cubist Pharmaceuticals Inc. for $8.4 billion in cash to add products to help fight the growing threat of drug-resistant bacteria. Merck will begin a $102-a-share tender offer for Cubist, the companies said in a statement Monday. Cubist has said it plans to introduce four new drugs by 2020 to combat bacterial infections that are resistant to other treatments because of overuse.Cubist surged 36 percent to $100.81 at 9:43 a.m. New York time. Cubist's products may complement Merck's own infectious disease program.Cubist already had an approved drug that works against the bacteria, which cause infectious diarrhea.
FOLLOW THIS ARTICLE